JP2011502501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011502501A5 JP2011502501A5 JP2010532629A JP2010532629A JP2011502501A5 JP 2011502501 A5 JP2011502501 A5 JP 2011502501A5 JP 2010532629 A JP2010532629 A JP 2010532629A JP 2010532629 A JP2010532629 A JP 2010532629A JP 2011502501 A5 JP2011502501 A5 JP 2011502501A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- nucleobases
- modified
- nucleobase
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 38
- 150000001875 compounds Chemical class 0.000 claims 15
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- 241000700605 Viruses Species 0.000 claims 9
- 230000029812 viral genome replication Effects 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 7
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 230000003612 virological effect Effects 0.000 claims 7
- 230000002401 inhibitory effect Effects 0.000 claims 6
- 230000000295 complement effect Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 108020004414 DNA Proteins 0.000 claims 3
- 241001493065 dsRNA viruses Species 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000010076 replication Effects 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 2
- 101710163270 Nuclease Proteins 0.000 claims 2
- 241001631646 Papillomaviridae Species 0.000 claims 2
- 241000710961 Semliki Forest virus Species 0.000 claims 2
- 108700005077 Viral Genes Proteins 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000010839 reverse transcription Methods 0.000 claims 2
- JHEKNTQSGTVPAO-UHFFFAOYSA-N 2-amino-8-sulfanylidene-7,9-dihydro-3h-purin-6-one Chemical compound N1C(N)=NC(=O)C2=C1NC(=S)N2 JHEKNTQSGTVPAO-UHFFFAOYSA-N 0.000 claims 1
- OFJNVANOCZHTMW-UHFFFAOYSA-N 5-hydroxyuracil Chemical compound OC1=CNC(=O)NC1=O OFJNVANOCZHTMW-UHFFFAOYSA-N 0.000 claims 1
- MIHCRNZMESVPJI-UHFFFAOYSA-N 5-sulfanyl-1h-pyrimidine-2,4-dione Chemical compound SC1=CNC(=O)NC1=O MIHCRNZMESVPJI-UHFFFAOYSA-N 0.000 claims 1
- NLLCDONDZDHLCI-UHFFFAOYSA-N 6-amino-5-hydroxy-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1O NLLCDONDZDHLCI-UHFFFAOYSA-N 0.000 claims 1
- UGQXLWWNSMGEBY-UHFFFAOYSA-N 6-amino-5-sulfanyl-1h-pyrimidin-2-one Chemical compound NC1=NC(=O)NC=C1S UGQXLWWNSMGEBY-UHFFFAOYSA-N 0.000 claims 1
- BHVOFCPOXNYVCE-UHFFFAOYSA-N 6-amino-7,9-dihydropurine-8-thione Chemical compound NC1=NC=NC2=C1NC(=S)N2 BHVOFCPOXNYVCE-UHFFFAOYSA-N 0.000 claims 1
- CLGFIVUFZRGQRP-UHFFFAOYSA-N 7,8-dihydro-8-oxoguanine Chemical compound O=C1NC(N)=NC2=C1NC(=O)N2 CLGFIVUFZRGQRP-UHFFFAOYSA-N 0.000 claims 1
- RGKBRPAAQSHTED-UHFFFAOYSA-N 8-oxoadenine Chemical compound NC1=NC=NC2=C1NC(=O)N2 RGKBRPAAQSHTED-UHFFFAOYSA-N 0.000 claims 1
- 241000710929 Alphavirus Species 0.000 claims 1
- 229910052684 Cerium Inorganic materials 0.000 claims 1
- 241000388186 Deltapapillomavirus 4 Species 0.000 claims 1
- 229910052692 Dysprosium Inorganic materials 0.000 claims 1
- 229910052691 Erbium Inorganic materials 0.000 claims 1
- 229910052693 Europium Inorganic materials 0.000 claims 1
- 229910052688 Gadolinium Inorganic materials 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 229910052689 Holmium Inorganic materials 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 241000701806 Human papillomavirus Species 0.000 claims 1
- 229910052765 Lutetium Inorganic materials 0.000 claims 1
- 229910052779 Neodymium Inorganic materials 0.000 claims 1
- 108091092724 Noncoding DNA Proteins 0.000 claims 1
- 229910052777 Praseodymium Inorganic materials 0.000 claims 1
- 229910052773 Promethium Inorganic materials 0.000 claims 1
- 229910052772 Samarium Inorganic materials 0.000 claims 1
- 229910052771 Terbium Inorganic materials 0.000 claims 1
- 229910052775 Thulium Inorganic materials 0.000 claims 1
- 229910052769 Ytterbium Inorganic materials 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 claims 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 claims 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 claims 1
- 229910052747 lanthanoid Inorganic materials 0.000 claims 1
- 150000002602 lanthanoids Chemical class 0.000 claims 1
- 229910052746 lanthanum Inorganic materials 0.000 claims 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 claims 1
- VQMWBBYLQSCNPO-UHFFFAOYSA-N promethium atom Chemical compound [Pm] VQMWBBYLQSCNPO-UHFFFAOYSA-N 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 108091008025 regulatory factors Proteins 0.000 claims 1
- 102000037983 regulatory factors Human genes 0.000 claims 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98554807P | 2007-11-05 | 2007-11-05 | |
| US60/985,548 | 2007-11-05 | ||
| US5768508P | 2008-05-30 | 2008-05-30 | |
| US61/057,685 | 2008-05-30 | ||
| PCT/FI2008/050633 WO2009060122A2 (en) | 2007-11-05 | 2008-11-05 | Use of oligonucleotides with modified bases as antiviral agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011502501A JP2011502501A (ja) | 2011-01-27 |
| JP2011502501A5 true JP2011502501A5 (enExample) | 2011-07-21 |
| JP5710977B2 JP5710977B2 (ja) | 2015-04-30 |
Family
ID=40551515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532629A Expired - Fee Related JP5710977B2 (ja) | 2007-11-05 | 2008-11-05 | 抗ウイルス薬としての修飾塩基を含むオリゴヌクレオチドの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20110171287A1 (enExample) |
| EP (1) | EP2212420A2 (enExample) |
| JP (1) | JP5710977B2 (enExample) |
| CN (1) | CN101970662A (enExample) |
| AU (1) | AU2008324066A1 (enExample) |
| BR (1) | BRPI0819191A2 (enExample) |
| CA (1) | CA2704549A1 (enExample) |
| MX (1) | MX2010004983A (enExample) |
| WO (1) | WO2009060122A2 (enExample) |
| ZA (1) | ZA201003234B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2704560A1 (en) * | 2007-11-05 | 2009-05-14 | Baltic Technology Development, Ltd. | Use of oligonucleotides with modified bases in hybridization of nucleic acids |
| US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
| WO2009144365A1 (en) * | 2008-05-30 | 2009-12-03 | Baltic Technology Development, Ltd. | Use of oligonucleotides with modified bases as antiviral agents |
| US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
| PL2545182T4 (pl) | 2010-03-08 | 2017-11-30 | Monsanto Technology Llc | Cząsteczki polinukeotydu do regulacji genów w roślinach |
| UA115535C2 (uk) | 2011-09-13 | 2017-11-27 | Монсанто Текнолоджи Ллс | Спосіб та композиція для боротьби з бур'янами (варіанти) |
| MX377067B (es) | 2011-09-13 | 2025-03-07 | Monsanto Technology Llc | Métodos y composiciones para el control de malezas. |
| UA116088C2 (uk) | 2011-09-13 | 2018-02-12 | Монсанто Текнолоджи Ллс | Спосіб та композиція для боротьби з бур'янами (варіанти) |
| WO2013040117A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and compositions for weed control |
| WO2013040005A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
| US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
| CA2848680C (en) | 2011-09-13 | 2020-05-19 | Monsanto Technology Llc | Methods and compositions for weed control |
| CN103975068A (zh) | 2011-09-13 | 2014-08-06 | 孟山都技术公司 | 用于杂草控制的方法和组合物 |
| EP2755988B1 (en) | 2011-09-13 | 2018-08-22 | Monsanto Technology LLC | Methods and compositions for weed control |
| US9840715B1 (en) | 2011-09-13 | 2017-12-12 | Monsanto Technology Llc | Methods and compositions for delaying senescence and improving disease tolerance and yield in plants |
| US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
| US9920326B1 (en) | 2011-09-14 | 2018-03-20 | Monsanto Technology Llc | Methods and compositions for increasing invertase activity in plants |
| AR091143A1 (es) | 2012-05-24 | 2015-01-14 | Seeds Ltd Ab | Composiciones y metodos para silenciar la expresion genetica |
| US20150267192A1 (en) * | 2012-06-08 | 2015-09-24 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| FI3622810T3 (fi) | 2012-09-24 | 2024-03-21 | Seminis Vegetable Seeds Inc | Menetelmät ja koostumukset kasvituotteiden säilyvyyden pidentämiseksi |
| MX364070B (es) | 2012-10-18 | 2019-04-10 | Monsanto Technology Llc | Métodos y composiciones para el control de plagas vegetales. |
| US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
| FR2997705B1 (fr) * | 2012-11-08 | 2015-10-16 | Nicolas Ugolin | Nucleotide 3' bloquant la traduction des proteines (sasb) |
| CN105358695B (zh) | 2013-01-01 | 2019-07-12 | A.B.种子有限公司 | 将dsRNA引入植物种子以调节基因表达的方法 |
| US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
| AR094492A1 (es) | 2013-01-15 | 2015-08-05 | Monsanto Technology Llc | Métodos y composiciones para el control de pestes vegetales |
| US10000767B2 (en) | 2013-01-28 | 2018-06-19 | Monsanto Technology Llc | Methods and compositions for plant pest control |
| EP2971185A4 (en) | 2013-03-13 | 2017-03-08 | Monsanto Technology LLC | Methods and compositions for weed control |
| UA121846C2 (uk) | 2013-03-13 | 2020-08-10 | Монсанто Текнолоджи Ллс | Спосіб та гербіцидна композиція для контролю видів рослини роду lolium |
| US20140283211A1 (en) | 2013-03-14 | 2014-09-18 | Monsanto Technology Llc | Methods and Compositions for Plant Pest Control |
| US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
| US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
| MX359191B (es) | 2013-07-19 | 2018-09-18 | Monsanto Technology Llc | Composiciones y métodos para controlar leptinotarsa. |
| UY35817A (es) | 2013-11-04 | 2015-05-29 | Us Agriculture | ?composiciones y métodos para controlar infestaciones de plagas y parásitos de los artrópodos?. |
| UA119253C2 (uk) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Спосіб боротьби із вірусом у кліща varroa та у бджіл |
| EP3116303B1 (en) | 2014-01-15 | 2020-07-22 | Monsanto Technology LLC | Methods and compositions for weed control using epsps polynucleotides |
| EP3420809A1 (en) | 2014-04-01 | 2019-01-02 | Monsanto Technology LLC | Compositions and methods for controlling insect pests |
| AU2015280252A1 (en) | 2014-06-23 | 2017-01-12 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via RNA interference |
| WO2015200539A1 (en) | 2014-06-25 | 2015-12-30 | Monsanto Technology Llc | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
| WO2016018887A1 (en) | 2014-07-29 | 2016-02-04 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
| AU2015305482B2 (en) * | 2014-08-19 | 2021-04-01 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
| PL3256589T3 (pl) | 2015-01-22 | 2022-02-21 | Monsanto Technology Llc | Kompozycje i sposoby kontrolowania leptinotarsa |
| EP3302053B1 (en) | 2015-06-02 | 2021-03-17 | Monsanto Technology LLC | Compositions and methods for delivery of a polynucleotide into a plant |
| EP3302030A4 (en) | 2015-06-03 | 2019-04-24 | Monsanto Technology LLC | METHOD AND COMPOSITIONS FOR INTRODUCING NUCLEIC ACIDS IN PLANTS |
| US10975387B2 (en) | 2016-01-26 | 2021-04-13 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
| EP4319879A4 (en) * | 2022-06-13 | 2025-01-01 | Fikrettin Sahin | Use of lutetium salt compounds for antiviral effect |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69032134T2 (de) * | 1989-12-04 | 1998-07-23 | Isis Pharmaceuticals, Inc., Carlsfeld, Calif. | Antisense oligonukleotidhemmung von papillomavirus |
| ATE239484T1 (de) * | 1991-10-24 | 2003-05-15 | Isis Pharmaceuticals Inc | Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen |
| US5684149A (en) * | 1993-01-22 | 1997-11-04 | Research Foundation Of State University Of New York | Metal complexes for promoting catalytic cleavage of RNA by transesterification |
| DE4415370A1 (de) * | 1994-05-02 | 1995-11-09 | Hoechst Ag | Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung |
| US20040171030A1 (en) * | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation |
| US20030064944A1 (en) * | 2001-06-21 | 2003-04-03 | Isis Pharmaceuticals Inc. | Antisense modulation of transforming growth factor beta receptor II expression |
| AU2003241621A1 (en) * | 2002-05-24 | 2003-12-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides having modified nucleoside units |
| AU2003248708A1 (en) * | 2002-06-17 | 2003-12-31 | Isis Pharmaceuticals, Inc. | Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation |
| CN101160401A (zh) * | 2005-02-24 | 2008-04-09 | 科勒制药集团公司 | 免疫刺激寡核苷酸 |
| JP2009535383A (ja) * | 2006-05-03 | 2009-10-01 | バルティック テクロノジー デヴェロプメント，リミテッド | 強く結合した塩基で修飾されたオリゴヌクレオチドと人工ヌクレアーゼを組み合わせたアンチセンス作用物質 |
-
2008
- 2008-11-05 AU AU2008324066A patent/AU2008324066A1/en not_active Abandoned
- 2008-11-05 BR BRPI0819191A patent/BRPI0819191A2/pt not_active IP Right Cessation
- 2008-11-05 CA CA2704549A patent/CA2704549A1/en not_active Abandoned
- 2008-11-05 EP EP08846868A patent/EP2212420A2/en not_active Withdrawn
- 2008-11-05 WO PCT/FI2008/050633 patent/WO2009060122A2/en not_active Ceased
- 2008-11-05 MX MX2010004983A patent/MX2010004983A/es active IP Right Grant
- 2008-11-05 CN CN2008801234555A patent/CN101970662A/zh active Pending
- 2008-11-05 US US12/741,531 patent/US20110171287A1/en not_active Abandoned
- 2008-11-05 JP JP2010532629A patent/JP5710977B2/ja not_active Expired - Fee Related
-
2010
- 2010-05-07 ZA ZA2010/03234A patent/ZA201003234B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011502501A5 (enExample) | ||
| JP2012510297A5 (enExample) | ||
| AU2016328645C1 (en) | Compositions and methods for synthesizing 5'-Capped RNAs | |
| JP2012136542A5 (enExample) | ||
| JP7348922B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP2015504650A5 (enExample) | ||
| JP2008513012A5 (enExample) | ||
| JP2016502858A5 (enExample) | ||
| CN102124020B (zh) | 自回避分子识别系统用于dna扩增 | |
| JP2019519218A5 (enExample) | ||
| JP2018519835A5 (enExample) | ||
| JP2018507711A5 (enExample) | ||
| JP2009532044A5 (enExample) | ||
| JP2015511821A5 (enExample) | ||
| NZ598943A (en) | Hbv antisense inhibitors | |
| JP2016533761A5 (enExample) | ||
| AU2019247645A1 (en) | Use of FUBP1 inhibitors for treating hepatitis B virus infection | |
| JP2019529406A5 (enExample) | ||
| JP2011502502A5 (enExample) | ||
| JP2021505129A5 (enExample) | ||
| JP2019533472A5 (enExample) | ||
| JP2021500016A5 (enExample) | ||
| JP2015532097A5 (enExample) | ||
| JP2013537404A5 (enExample) | ||
| WO2007042899B1 (en) | Human microrna targets in hiv genome and a method of identification thereof |